Pluristem Therapeutics Inc. (NASDAQ:PSTI) has received a consensus rating of “Buy” from the six analysts that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $4.00.
Several equities analysts have commented on PSTI shares. Maxim Group set a $3.00 price target on shares of Pluristem Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, February 21st. Zacks Investment Research downgraded shares of Pluristem Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, March 20th. HC Wainwright set a $4.00 price target on shares of Pluristem Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, May 1st. MED restated a “positive” rating on shares of Pluristem Therapeutics in a research note on Monday, April 23rd. Finally, ValuEngine upgraded shares of Pluristem Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Wednesday, May 2nd.
Pluristem Therapeutics opened at $1.40 on Friday, MarketBeat.com reports. The firm has a market capitalization of $156.32 million, a price-to-earnings ratio of -4.38 and a beta of 0.27. Pluristem Therapeutics has a 52 week low of $1.40 and a 52 week high of $1.42.
Pluristem Therapeutics (NASDAQ:PSTI) last posted its quarterly earnings results on Thursday, May 10th. The biotechnology company reported ($0.01) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.09) by $0.08. sell-side analysts forecast that Pluristem Therapeutics will post -0.29 EPS for the current year.
In related news, Director Mark Germain sold 45,873 shares of the business’s stock in a transaction on Friday, March 16th. The shares were sold at an average price of $1.48, for a total transaction of $67,892.04. Following the completion of the transaction, the director now owns 525,584 shares in the company, valued at $777,864.32. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 7.20% of the company’s stock.
An institutional investor recently raised its position in Pluristem Therapeutics stock. ARK Investment Management LLC increased its position in shares of Pluristem Therapeutics Inc. (NASDAQ:PSTI) by 363.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 290,922 shares of the biotechnology company’s stock after purchasing an additional 228,149 shares during the period. ARK Investment Management LLC owned 0.26% of Pluristem Therapeutics worth $401,000 at the end of the most recent quarter. Institutional investors own 4.13% of the company’s stock.
Pluristem Therapeutics Company Profile
Pluristem Therapeutics Inc, together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders.
Receive News & Ratings for Pluristem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.